ALX Oncology ALXO Stock
ALX Oncology Price Chart
ALX Oncology ALXO Financial and Trading Overview
| ALX Oncology stock price | 1.67 USD |
| Previous Close | 1.9 USD |
| Open | 1.89 USD |
| Bid | 1.36 USD x 200 |
| Ask | 1.81 USD x 100 |
| Day's Range | 1.79 - 1.89 USD |
| 52 Week Range | 0.4 - 2.66 USD |
| Volume | 1.02M USD |
| Avg. Volume | 947.21K USD |
| Market Cap | 242.21M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.49 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.6 USD |
ALXO Valuation Measures
| Enterprise Value | 110.4M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.3454762 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.5999999 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.264 |
Trading Information
ALX Oncology Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 239.89% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 2.66 USD |
| 52 Week Low | 0.4 USD |
| 50-Day Moving Average | 1.89 USD |
| 200-Day Moving Average | 1.64 USD |
ALXO Share Statistics
| Avg. Volume (3 month) | 947.21K USD |
| Avg. Daily Volume (10-Days) | 1.22M USD |
| Shares Outstanding | 134.56M |
| Float | 107.02M |
| Short Ratio | 1.42 |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 78.77% |
| Shares Short | 1.38M |
| Short % of Float | 1.14% |
| Short % of Shares Outstanding | 1.02% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -36.75% |
| Return on Equity (ttm) | -74.16% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -87347000 USD |
| Net Income Avi to Common (ttm) | -88868000 USD |
| Diluted EPS (ttm) | -1.49 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 140.32M USD |
| Total Cash Per Share (mrq) | 1.04 USD |
| Total Debt (mrq) | 8.51M USD |
| Total Debt/Equity (mrq) | 5.62 USD |
| Current Ratio (mrq) | 7.214 |
| Book Value Per Share (mrq) | 1.125 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -78127000 USD |
| Levered Free Cash Flow (ttm) | -43268376 USD |
Profile of ALX Oncology
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 323 Allerton Avenue |
| ZIP | 94080 |
| Phone | 650 466 7125 |
| Website | https://www.alxoncology.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 43 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Q&A For ALX Oncology Stock
What is a current ALXO stock price?
ALX Oncology ALXO stock price today per share is 1.67 USD.
How to purchase ALX Oncology stock?
You can buy ALXO shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ALX Oncology?
The stock symbol or ticker of ALX Oncology is ALXO.
Which industry does the ALX Oncology company belong to?
The ALX Oncology industry is Biotechnology.
How many shares does ALX Oncology have in circulation?
The max supply of ALX Oncology shares is 134.56M.
What is ALX Oncology Price to Earnings Ratio (PE Ratio)?
ALX Oncology PE Ratio is now.
What was ALX Oncology earnings per share over the trailing 12 months (TTM)?
ALX Oncology EPS is -1.49 USD over the trailing 12 months.
Which sector does the ALX Oncology company belong to?
The ALX Oncology sector is Healthcare.
ALX Oncology ALXO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}